Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 5/20 | 0.80 |
| ▸ | FES | P07332 | 3/20 | 0.75 |
| ▸ | FLT3 | P36888 | 3/20 | 0.75 |
| ▸ | ALK | Q9UM73 | 15/20 | 0.64 |
| ▸ | GAK | O14976 | 3/20 | 0.63 |
| ▸ | INSR | P06213 | 3/20 | 0.63 |
| ▸ | IGF1R | P08069 | 3/20 | 0.63 |
| ▸ | LTK | P29376 | 3/20 | 0.63 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.63 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.63 |
| ▸ | TNK1 | Q13470 | 3/20 | 0.63 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.63 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.63 |
| ▸ | INSRR | P14616 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | CLK1 | P49759 | 2/20 | 0.63 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.62 |
| ▸ | PLK4 | O00444 | 2/20 | 0.62 |
| ▸ | ERN1 | O75460 | 2/20 | 0.62 |
| ▸ | STK10 | O94804 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18018799 | 0.94 | TTK (0.70) | TTKFESFLT3ALKGAK | |
| SCHEMBL18018865 | 0.92 | TTK (0.68) | TTKFESFLT3ALKGAK | |
| SCHEMBL30381944 | 0.89 | TTK (1.00) | TTKFESFLT3ALKGAK | |
| SCHEMBL23841115 | 0.89 | TTK (0.64) | TTKFESFLT3ALKGAK | |
| SCHEMBL18018886 | 0.89 | TTK (0.63) | TTKFESFLT3ALKGAK | |
| SCHEMBL17731666 | 0.87 | TTK (1.00) | TTKFESFLT3ALKGAK | |
| SCHEMBL3954048 | 0.86 | FES (1.00) | TTKFESFLT3ALKGAK | |
| SCHEMBL14866359 | 0.85 | TTK (0.81) | TTKFESFLT3ALKGAK | |
| SCHEMBL14866370 | 0.85 | ALK (0.80) | TTKFESFLT3ALKGAK | |
| SCHEMBL22985929 | 0.84 | TTK (0.57) | TTKFESFLT3ALKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023233148-A1 | CANCER THERAPY | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL, (GB) | 2023-12-07 | — | — | WO | disclosed |
| US-11207321-B2 | Methods and medical uses | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-12-28 | — | — | US | disclosed |
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200171032-A1 | METHODS AND MEDICAL USES | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200138815-A1 | METHODS AND MEDICAL USES | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2020-05-07 | — | — | US | disclosed |
| WO-2016130920-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138815-A1 | METHODS AND MEDICAL USES | CDK4, CDK1, CDK5R1 | TTK 358/4885FES 1765/4885FLT3 889/4885 |
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | LRRK2, PARK7, PINK1 | TTK 1181/4885FES 4037/4885FLT3 4356/4885 |
| US-11207321-B2 | Methods and medical uses | CDK4, CDK1, CDK5R1 | TTK 358/4885FES 1765/4885FLT3 889/4885 |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | LRRK2, PARK7, PINK1 | TTK 1181/4885FES 4037/4885FLT3 4356/4885 |
| US-20200171032-A1 | METHODS AND MEDICAL USES | BRCA1, GPER1, SERPINB1 | TTK 1379/4885FES 2879/4885FLT3 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.